MedTrace Logo

Merestinib on Bone Metastases in Subjects With Breast Cancer

NCT03292536 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-01-08

No results posted yet for this study

Summary

This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.

Conditions

Interventions

DRUG

Merestinib

\*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\* Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-11
Primary Completion
2019-06-24
Completion
2019-06-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03292536 on ClinicalTrials.gov